Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease
ConclusionRomosozumab for 12 months is an effective and well-tolerated treatment option for Japanese patients with osteoporosis and mild-to-moderate CKD.
Source: Journal of Bone and Mineral Metabolism - Category: Orthopaedics Source Type: research
More News: Chronic Kidney Disease | Japan Health | Orthopaedics | Osteoporosis | Study | Urology & Nephrology | Women